The Compassion and Attention Longitudinal Meditation Study (CALM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01251341|
Recruitment Status : Completed
First Posted : December 1, 2010
Last Update Posted : December 5, 2014
|Condition or disease||Intervention/treatment||Phase|
|Immune System Processes Inflammatory Activation and Modulation ANS Function||Behavioral: Cognitive-Based Compassion Training Behavioral: Mindful Attention Training Behavioral: Adult Health Education Curriculum||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||226 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Mechanisms of Meditation|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||May 2014|
|Actual Study Completion Date :||May 2014|
|Experimental: Compassion Meditation Group||
Behavioral: Cognitive-Based Compassion Training
Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
|Active Comparator: Health Education and Wellness Group||
Behavioral: Adult Health Education Curriculum
Eight week training in health and wellness, using a curriculum developed specifically for this study.
|Experimental: Mindful Attention Training||
Behavioral: Mindful Attention Training
Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
- Effects of compassion meditation on inflammatory and behavioral responses to psychosocial stress using a longitudinal design. [ Time Frame: Five years ]Innate immune cytokine responses will be assessed before and after a psychosocial stressor to evaluate the differential impact of the two interventions and the active control.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01251341
|United States, Georgia|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Charles Raison, MD||University of Arizona|
|Study Director:||Lobsang Tenzin Negi, PhD||Emory University|